FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966794384> ?p ?o ?g. }

• W1966794384 endingPage "1561" @default.
• W1966794384 startingPage "1555" @default.
• W1966794384 abstract "BackgroundThere is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL.Patients and methodsPatients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C.ResultsThirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity.ConclusionThe bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL." @default.
• W1966794384 created "2016-06-24" @default.
• W1966794384 creator A5002061358 @default.
• W1966794384 creator A5013766565 @default.
• W1966794384 creator A5019790026 @default.
• W1966794384 creator A5023008376 @default.
• W1966794384 creator A5025724403 @default.
• W1966794384 creator A5030588675 @default.
• W1966794384 creator A5030974449 @default.
• W1966794384 creator A5031216970 @default.
• W1966794384 creator A5034388787 @default.
• W1966794384 creator A5036560737 @default.
• W1966794384 creator A5042776012 @default.
• W1966794384 creator A5051274168 @default.
• W1966794384 creator A5052071966 @default.
• W1966794384 creator A5058383890 @default.
• W1966794384 creator A5063319536 @default.
• W1966794384 creator A5063660245 @default.
• W1966794384 creator A5068144072 @default.
• W1966794384 creator A5068452218 @default.
• W1966794384 creator A5076521693 @default.
• W1966794384 creator A5077435007 @default.
• W1966794384 date "2012-06-01" @default.
• W1966794384 modified "2023-10-15" @default.
• W1966794384 title "Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS" @default.
• W1966794384 cites W1912693401 @default.
• W1966794384 cites W1969049855 @default.
• W1966794384 cites W1996537666 @default.
• W1966794384 cites W2019049627 @default.
• W1966794384 cites W2021670721 @default.
• W1966794384 cites W2044993853 @default.
• W1966794384 cites W2053292153 @default.
• W1966794384 cites W2106904404 @default.
• W1966794384 cites W2111204298 @default.
• W1966794384 cites W2111530307 @default.
• W1966794384 cites W2125684345 @default.
• W1966794384 cites W2130669641 @default.
• W1966794384 cites W2137422418 @default.
• W1966794384 cites W2147422161 @default.
• W1966794384 cites W2151092645 @default.
• W1966794384 cites W2153569820 @default.
• W1966794384 cites W2980059567 @default.
• W1966794384 doi "https://doi.org/10.1093/annonc/mdr450" @default.
• W1966794384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22012966" @default.
• W1966794384 hasPublicationYear "2012" @default.
• W1966794384 type Work @default.
• W1966794384 sameAs 1966794384 @default.
• W1966794384 citedByCount "39" @default.
• W1966794384 countsByYear W19667943842012 @default.
• W1966794384 countsByYear W19667943842013 @default.
• W1966794384 countsByYear W19667943842014 @default.
• W1966794384 countsByYear W19667943842015 @default.
• W1966794384 countsByYear W19667943842016 @default.
• W1966794384 countsByYear W19667943842017 @default.
• W1966794384 countsByYear W19667943842018 @default.
• W1966794384 countsByYear W19667943842019 @default.
• W1966794384 countsByYear W19667943842020 @default.
• W1966794384 crossrefType "journal-article" @default.
• W1966794384 hasAuthorship W1966794384A5002061358 @default.
• W1966794384 hasAuthorship W1966794384A5013766565 @default.
• W1966794384 hasAuthorship W1966794384A5019790026 @default.
• W1966794384 hasAuthorship W1966794384A5023008376 @default.
• W1966794384 hasAuthorship W1966794384A5025724403 @default.
• W1966794384 hasAuthorship W1966794384A5030588675 @default.
• W1966794384 hasAuthorship W1966794384A5030974449 @default.
• W1966794384 hasAuthorship W1966794384A5031216970 @default.
• W1966794384 hasAuthorship W1966794384A5034388787 @default.
• W1966794384 hasAuthorship W1966794384A5036560737 @default.
• W1966794384 hasAuthorship W1966794384A5042776012 @default.
• W1966794384 hasAuthorship W1966794384A5051274168 @default.
• W1966794384 hasAuthorship W1966794384A5052071966 @default.
• W1966794384 hasAuthorship W1966794384A5058383890 @default.
• W1966794384 hasAuthorship W1966794384A5063319536 @default.
• W1966794384 hasAuthorship W1966794384A5063660245 @default.
• W1966794384 hasAuthorship W1966794384A5068144072 @default.
• W1966794384 hasAuthorship W1966794384A5068452218 @default.
• W1966794384 hasAuthorship W1966794384A5076521693 @default.
• W1966794384 hasAuthorship W1966794384A5077435007 @default.
• W1966794384 hasBestOaLocation W19667943841 @default.
• W1966794384 hasConcept C126322002 @default.
• W1966794384 hasConcept C141071460 @default.
• W1966794384 hasConcept C143998085 @default.
• W1966794384 hasConcept C2776364478 @default.
• W1966794384 hasConcept C2776694085 @default.
• W1966794384 hasConcept C2776755627 @default.
• W1966794384 hasConcept C2777063308 @default.
• W1966794384 hasConcept C2777478702 @default.
• W1966794384 hasConcept C2777525834 @default.
• W1966794384 hasConcept C2777866208 @default.
• W1966794384 hasConcept C2778336483 @default.
• W1966794384 hasConcept C2779338263 @default.
• W1966794384 hasConcept C2779429289 @default.
• W1966794384 hasConcept C2780401358 @default.
• W1966794384 hasConcept C2780653079 @default.
• W1966794384 hasConcept C2780775027 @default.
• W1966794384 hasConcept C2781413609 @default.
• W1966794384 hasConcept C71924100 @default.
• W1966794384 hasConcept C90924648 @default.

• next